BioSpace News Archive

IRLAB takes important steps expanding the development pipeline and nominates a new drug candidate, IRL757, from the P001 discovery program.

Neuromagen Pharma Ltd., a company developing a new class of drugs for the treatment of degenerative and senescence-associated diseases, announced the approval by the Israel Innovation Authority of a NIS 1.3 million grant.

On March 19, the Media Briefing on Prevention and Control of COVID-19 with Lianhua Qingwen Capsules, a patented Chinese medicine developed and produced by Yiling Pharmaceutical, was convened in Shijiazhuang City, Hebei Province, at which the in vitro experimental results of Lianhua Qingwen Capsules against SARS-CoV-2 Omicron variant by Guangzhou Institute of Respiratory Health recently were published.

RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, announced the appointment of Christopher Wick to the newly created position of Senior Director, Head of U.S. Sales.

Evotec SE announced that the Company received a € 3 m milestone payment from Bayer AG as a result of another promising small molecule from the Evotec-Bayer multi-target research alliance advancing into Phase II clinical development as a potential treatment for diabetic neuropathic pain.

Osler Diagnostics is pleased to announce the appointment of Chris Smith as Chairman of the Board of Directors and David Berry as a Non-Executive Director, with immediate effect.

bioLytical Laboratories Inc. announced that it is launching a new platform, iStatis, and has received its CE Mark for immediate market entry into Europe for its iStatis COVID-19 Antigen Home Test.

Avacta Group plc announces the appointment of Christina Coughlin, M.D., Ph.D., as Non-executive Director to the Board with immediate effect.

Vaxxinity, Inc. today announced that Peter Powchik, M.D. is joining its Board of Directors and will be retiring as Vaxxinity’s Executive Vice President, Research & Development.

Recro Pharma, Inc. today announced that it is changing its name to Societal CDMO, Inc. to reflect the corporate transformation that has taken place primarily as a result of its acquisition and successful integration of IriSys, Inc. into the organization.